Hypothesis

Rapamycin's lifespan extension requires functional BAG3‑mediated chaperone‑assisted selective autophagy (CASA) that is activated by reduced cellular mechanical tension downstream of mTORC1 inhibition.

Mechanistic Rationale

• mTORC1 promotes actin polymerization and myosin II activity, raising intracellular tension.
• Inhibition of mTORC1 by rapamycin lowers RhoA‑ROCK signaling, decreasing stress‑fiber formation and overall tension.
• BAG3 contains a mechanical‑sensing domain that binds exposed hydrophobic patches on misfolded cytoskeletal proteins when tension drops, recruiting Hsp70 and LC3 to initiate CASA.
• Thus, rapamycin does not merely upregulate BAG3 expression; it changes the subcellular context that enables BAG3 to act as a mechanostat, shifting clearance from the proteasome to autophagy.
• If BAG3 cannot sense tension (e.g., mutation of its mechanosensing domain), rapamycin‑induced CASA fails, and lifespan extension is lost.

Experimental Plan

• Generate a knock‑in mouse line expressing BAG3 with a point mutation in its mechanosensing domain (e.g., L145P) that abolishes tension‑dependent activation but preserves basal expression.
• Treat wild‑type and mutant cohorts with rapamycin (14 ppm chow) starting at 12 months of age.
• Monitor survival, calculate median and maximal lifespan.
• In parallel, harvest skeletal muscle and heart at 6 months post‑treatment to assess:
  • CASA flux using a tandem fluorescent‑LC3 reporter coupled to a known BAG3 substrate (e.g., mutant desmin).
  • Levels of phosphorylated cofilin and F‑actin/G‑actin ratio as readouts of tension.
  • Autophagosome‑lysosome fusion via LysoTracker and LC3‑II turnover with bafilomycin A1.
• Include control groups receiving vehicle and, where possible, a genetic mTORC1 hypomorph (Raptor heterozygous) to confirm pathway specificity.

Predicted Outcomes

• If the hypothesis is correct, rapamycin will extend lifespan in wild‑type mice but not in the BAG3 mechanosensor mutants, despite comparable drug exposure and mTORC1 inhibition (measured by p‑S6K).
• Mutants will show blunted CASA activation (reduced LC3‑II accumulation on desmin aggregates) and unchanged actin dynamics, indicating uncoupling of mTORC1 inhibition from proteostatic remodeling.
• Conversely, Raptor heterozygotes should phenocopy wild‑type rapamycin response, confirming that the effect stems from mTORC1 down‑regulation rather than off‑target actions.

Potential Caveats

• Compensatory up‑regulation of other BAG family members could mask the phenotype; therefore, double‑knock‑out or siRNA approaches may be needed in vitro.
• Systemic effects of rapamycin on immunity or metabolism could independently influence longevity; using inducible, tissue‑specific BAG3 mutants (e.g., muscle‑ or cardiomyocyte‑restricted) will help isolate the proteostatic arm.
• The mechanosensing domain of BAG3 may also interact with integrin‑FAK signaling; measuring focal adhesion kinase phosphorylation will clarify whether the observed tension changes are upstream or downstream of BAG3 activation.

Key References

• Rapamycin extends lifespan in mice, yeast, worms, and flies by inhibiting mTORC1, which activates protective stress‑response pathways like autophagy, thus mimicking hormesis rather than directly repairing accumulated damage1.
• Rapamycin's benefits arise from mimicking caloric restriction through reduced translation errors, enhanced autophagy, and dampened inflammation2.
• Even transient, late-life rapamycin treatment (3 months in middle-aged mice) produces persistent lifespan extension up to 60%3.
• BAG3 acts as a mechanosensor upregulated during stress and aging, coordinating selective autophagy of mechanically damaged proteins4.
• Concerns about side effects and limited evidence for longevity benefits in healthy adults5.